<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04062799</url>
  </required_header>
  <id_info>
    <org_study_id>IIBSP-NEU-2018-118</org_study_id>
    <nct_id>NCT04062799</nct_id>
  </id_info>
  <brief_title>Immunophenotype of Risk in Older Patients Admitted for Pneumonia</brief_title>
  <official_title>Identification of an Immunophenotype of Risk of Poor Prognosis in Elderly Patients Who Have Been Admitted for Pneumonia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fondo de Investigacion Sanitaria</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective is to evaluate if the immune risk phenotype (IRP) in patients who have been
      admitted for pneumonia predisposes to worse long-term outcomes. In addition, the association
      between the detected immunological alterations and clinical, functional, nutritional or
      comorbidity risk factors will be evaluated.

      If the hypothesis is confirmed, helpful immunological markers will be identified. This will
      be useful in clinical practice to identify patients who can benefit from an intervention and
      / or to identify the best time for vaccination. Otherwise, valuable information will be
      obtained on the interrelation between immunological, clinical, functional and nutritional
      aspects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective is to evaluate if the immune risk phenotype (IRP) in patients who have been
      admitted for pneumonia predisposes to worse long-term outcomes. In addition, the association
      between the detected immunological alterations and clinical, functional, nutritional or
      comorbidity risk factors will be evaluated.

      Methodology: Prospective observational study. It will include 149 patients ≥ 65 years
      admitted for pneumonia. After 30-45 days of pneumonia diagnosis, a complete clinical,
      functional, nutritional and immunological assessment will be carried out. FRI will be defined
      as a positive cytomegalovirus serology together with at least one of the following: CD4 / CD8
      &lt;1, CD8 T cells&gt; 600 / μl or negative CD28 T cells&gt; 300 / μl15. Mortality and re-admissions
      at 12 and 18 months will be evaluated.

      If the hypothesis is confirmed, helpful immunological markers will be identified. This will
      be useful in clinical practice to identify patients who can benefit from an intervention and
      / or to identify the best time for vaccination. Otherwise, valuable information will be
      obtained on the interrelation between immunological, clinical, functional and nutritional
      aspects.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 9, 2019</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Presence of the immune risk phenotype (IRP)</measure>
    <time_frame>18 months</time_frame>
    <description>To assess whether the presence of the immune risk phenotype (IRP) in patients who have been admitted for pneumonia predisposes to higher mortality after 18 months of pneumonia.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of readmissions</measure>
    <time_frame>18 months</time_frame>
    <description>To assess number of readmissions at 18 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunological markers other than IRP</measure>
    <time_frame>18 months</time_frame>
    <description>To evaluate if immunological markers other than IRP predispose to higher mortality or readmission rates</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunological profile</measure>
    <time_frame>18 months</time_frame>
    <description>To describe the basic immunological profile of the elderly who have been admitted due to pneumonia and its evolution after the acute phase.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunological alterations</measure>
    <time_frame>18 months</time_frame>
    <description>To study if there is an association between IRP and clinical, functional, nutritional, comorbidity risk factors or frailty/sarcopenia.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">149</enrollment>
  <condition>Age Associated Immune Deficiency</condition>
  <condition>Elderly Infection</condition>
  <condition>Pneumonia</condition>
  <condition>Nutrition Disorders in Old Age</condition>
  <condition>Frail Elderly Syndrome</condition>
  <condition>Sarcopenia</condition>
  <arm_group>
    <arm_group_label>Study cohort</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>no intervention</intervention_name>
    <description>It is an observationa study. There is no intervention.</description>
    <arm_group_label>Study cohort</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood samples
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients ≥ 65 years old admitted for pneumonia in the &quot;Hospital de la Santa Creu i Sant Pau
        in Barcelona&quot;.

        Pneumonia will be defined in the presence of a new infiltrate in the chest radiograph along
        with one or more compatible signs or symptoms: fever, chills, cough, expectoration or
        malaise.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients ≥ 65 years old admitted for pneumonia in the &quot;Hospital de la Santa Creu i
             Sant Pau in Barcelona&quot;.

        Exclusion Criteria:

          -  patients from another acute care hospital

          -  patients with HIV infection

          -  neutropenic patients (neutrophil count &lt;1000 / mm3)

          -  transplant patients

          -  patients in end-of-life situation

          -  not having written informed consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Olga H Torres, PhD MD</last_name>
    <phone>34932919000</phone>
    <phone_ext>5609</phone_ext>
    <email>otorres@santpau.cat</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital de la Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olga Torres, MD, PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>May 6, 2019</study_first_submitted>
  <study_first_submitted_qc>August 19, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 20, 2019</study_first_posted>
  <last_update_submitted>August 19, 2019</last_update_submitted>
  <last_update_submitted_qc>August 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 20, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Sarcopenia</mesh_term>
    <mesh_term>Nutrition Disorders</mesh_term>
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

